TRV120027 TFA, a beta-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages beta-arrestins while blocking G-protein signaling[1]. TRV120027 TFA induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R-beta-arrestin-1-TRPC3-PLCgamma at the plasma membrane. TRV120027 TFA inhibits angiotensin II-mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 TFA has the potential for the acute decompensated heart failure (ADHF) treatment[2].
Molecular Weight:
1040.10
Purity:
99.62
Formula:
C45H68F3N13O12
Target:
Angiotensin Receptor,Arrestin
Application Notes:
MCE Product type: Peptides
* VAT and and shipping costs not included. Errors and price changes excepted
